INDOCO
Indoco Remedies Limited
Each stock's 10,000-path forecast, rendered as light.
Indoco Remedies Limited (INDOCO) Stock Analysis & Case Study
Is INDOCO a good buy? The data-driven verdict.
Indoco Remedies Limited (INDOCO) trades at ₹222,on the numbers it high-risk on the numbers, a Downstox Snapshot Score of 25/100.
On the numbers, Indoco Remedies Limited (INDOCO) high-risk on the numbers, a Downstox Snapshot Score of 25/100, weighing expensive at 102.0× earnings, ROE of -9.4%, a 51% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
INDOCO fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How INDOCO ranks against the 2,373 companies in our screener
- INDOCO's market cap of 2,047 Cr ranks in the 51st percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- INDOCO's book value of ₹102 ranks in the 53rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- INDOCO's promoter holding of 58.9% ranks in the 49th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- INDOCO's 3-year profit (PAT) growth of -14.0% ranks in the 16th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- INDOCO's 3-year revenue growth of 3.0% ranks in the 30th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- INDOCO's debt-to-equity ratio of 1.16x is lower than 11% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is INDOCO overvalued? INDOCO P/E vs peers
INDOCO trades at 102.0× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
INDOCO share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of INDOCO history (-3%/yr drift, 45%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| INDOCO 2027 | ₹124 | ₹223 | ₹402 | +1% |
| INDOCO 2028 | ₹99 | ₹225 | ₹511 | +1% |
| INDOCO 2029 | ₹83 | ₹226 | ₹620 | +2% |
| INDOCO 2030 | ₹72 | ₹228 | ₹724 | +3% |
| INDOCO 2031 | ₹63 | ₹230 | ₹831 | +4% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability INDOCO goes up, or doubles?
The bull case for INDOCO
- Indoco Remedies Limited is part of the nifty500 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹620.
The bear case & risks
- INDOCO's P/E of 102.0x is lower than 11% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- INDOCO's Piotroski F-Score of 3/8 ranks in the 15th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- High historical volatility (45%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹83.
INDOCO volatility & expected range, how bumpy is the ride?
Over the last 9.8 years INDOCO compounded at -3%/year with annualized volatility of 45%. That volatility implies a 1-year 80% range of ₹124-₹402, the honest backbone behind any single price target.
INDOCO price forecast, the full 60-month probability fan
INDOCO price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds INDOCO hits common targets within the simulated horizon?
Full multi-horizon detail on the INDOCO price target & forecast page.
INDOCO Piotroski F-Score: 3/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. INDOCO scores 3/8, weak on the financial-strength checks.
INDOCO MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy INDOCO with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 36.80% | 2.7× |
| Zerodha | 50.00% | 2.0× |
| Groww | 40.00% | 2.5× |
| Dhan | 40.00% | 2.5× |
| Kotak Neo | 100.00% | 1.0× |
| Paytm Money | 37.96% | 2.6× |
| Pocketful | 50.00% | 2.0× |
| Fyers | 50.00% | 2.0× |
| Anand RathiCHEAPEST | 36.75% | 2.7× |
| Share India | 36.96% | 2.7× |
Compare every broker on the INDOCO MTF page.
About Indoco Remedies Limited: sector, index & market-cap context
Indoco Remedies Limited (INDOCO) is a small-cap NSE-listed company, with a market capitalisation of ₹2,047 Cr. See more stocks on our screener.
How the INDOCO Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Indoco Remedies Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
INDOCO analysis, FAQs
Is Indoco Remedies Limited (INDOCO) a good buy?
On the numbers, Indoco Remedies Limited (INDOCO) high-risk on the numbers, a Downstox Snapshot Score of 25/100, weighing expensive at 102.0× earnings, ROE of -9.4%, a 51% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is INDOCO overvalued or undervalued?
INDOCO trades at 102.0× earnings, expensive versus the ~22× long-run Nifty average.
What is the INDOCO share price target for 2031?
INDOCO's probability-weighted 2031 median target is ₹230, with an 80% range of ₹63-₹831 (10,000-path Monte-Carlo).
What is the probability INDOCO doubles in 5 years?
The modelled probability of INDOCO reaching ₹443 (2×) within 5 years is 26%.
What is the bull case for INDOCO?
Indoco Remedies Limited is part of the nifty500 universe with live, tracked fundamentals on Downstox.
What are the risks in INDOCO?
INDOCO's P/E of 102.0x is lower than 11% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. INDOCO's Piotroski F-Score of 3/8 ranks in the 15th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026. High historical volatility (45%/yr) means a wide, bumpy range of outcomes, size positions accordingly.